These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33872258)

  • 41. Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice.
    Schmidt HA; Rodolph M; Schaefer R; Baggaley R; Doherty M
    J Int AIDS Soc; 2022 Jul; 25(7):e25963. PubMed ID: 35903882
    [No Abstract]   [Full Text] [Related]  

  • 42. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
    Scheibe K; Urbańska A; Serwin K; Parczewski M
    Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start.
    Pinto RM; Hall E; Tomlin R
    J Assoc Nurses AIDS Care; 2023 Mar-Apr 01; 34(2):216-220. PubMed ID: 36662654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
    D'Amico R; Cenoz Gomis S; Moodley R; Van Solingen-Ristea R; Baugh B; Van Landuyt E; Van Eygen V; Min S; Cutrell A; Foster C; Chilton D; Allard SD; Ruiter A
    HIV Med; 2023 Feb; 24(2):202-211. PubMed ID: 35945163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The optimum implementation of long-acting injectable cabotegravir-rilpivirine in sub-Saharan Africa.
    Dawood H
    Lancet Glob Health; 2021 May; 9(5):e563-e564. PubMed ID: 33770512
    [No Abstract]   [Full Text] [Related]  

  • 47. Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
    Czarnogorski M; Benn P; McCoig C; Nwafor T; Griffith S; Sutton K; Harrington C; Saggu P; Yague I; Williams W; Español CM; Goodchild J; Fricker J; Patel P; D'Amico R
    J Acquir Immune Defic Syndr; 2022 Oct; 91(2):157-161. PubMed ID: 36094481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis.
    Ahluwalia AK; Inzaule S; Baggaley RC; Vitoria M; Schaefer R; Schmidt HA; Rodolph M; Giron A; Jordan MR
    AIDS; 2022 Nov; 36(13):1897-1898. PubMed ID: 36172874
    [No Abstract]   [Full Text] [Related]  

  • 49. Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.
    El-Haddad A; Erlich D
    Am Fam Physician; 2023 May; 107(5):545-546. PubMed ID: 37192084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection.
    Durham SH; Chahine EB
    Ann Pharmacother; 2021 Nov; 55(11):1397-1409. PubMed ID: 33593093
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment.
    Alberton F; Nozza S; Raccagni AR; Galli L; Spagnuolo V; Bossolasco S; Cernuschi M; Canetti D; Hasson H; Castagna A; Gianotti N
    J Med Virol; 2023 Jan; 95(1):e28330. PubMed ID: 36415058
    [No Abstract]   [Full Text] [Related]  

  • 52. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR
    Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transient Viremia in Young Adults With HIV After the Switch to Long-Acting Cabotegravir and Rilpivirine: Considerations for Dosing Schedule and Monitoring.
    Rakhmanina N; Richards K; Adeline Koay WL
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):e14-e17. PubMed ID: 36480701
    [No Abstract]   [Full Text] [Related]  

  • 54. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
    Flexner C; Owen A; Siccardi M; Swindells S
    Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
    Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy.
    Moffatt K; Tekko IA; Vora L; Volpe-Zanutto F; Hutton ARJ; Mistilis J; Jarrahian C; Akhavein N; Weber AD; McCarthy HO; Donnelly RF
    Pharm Res; 2023 Jul; 40(7):1673-1696. PubMed ID: 36224503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?
    Bettonte S; Berton M; Marzolini C
    Expert Opin Drug Metab Toxicol; 2023; 19(5):243-247. PubMed ID: 37293864
    [No Abstract]   [Full Text] [Related]  

  • 58. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
    Rusconi S; Santoro MM; Capetti AF; Gianotti N; Zazzi M
    Int J Antimicrob Agents; 2022 Sep; 60(3):106627. PubMed ID: 35760225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
    Bares SH; Scarsi KK
    Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic.
    Howe ZW; Norman S; Lueken AF; Huesgen E; Farmer EK; Jarrell K; Mathis JE; Bonham KW; Hahn J
    Pharmacotherapy; 2021 Aug; 41(8):686-699. PubMed ID: 34130357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.